Company intelligence / Profile preview

Cascadian Therapeutics

Seattle, Washington, United Statesbusinesswire.com ↗

Ownership: Private
Employees: ~12
Development stage: Phase 2

Overview

Cascadian Therapeutics’ lead asset was tucatinib, an oral, highly selective small-molecule inhibitor of HER2. Tucatinib demonstrated favorable tolerability and efficacy in combination with capecitabine and trastuzumab for patients with advanced or metastatic HER2-positive breast cancer, including those with brain metastases. The pivotal Phase 3 trial (“HER2CLIMB”) was ongoing at the time of the company’s acquisition by Seattle Genetics in March 2018[6][9][10].

Therapeutic areas: Oncology
Modalities: Small molecules (notably tyrosine kinase inhibitors)Monoclonal antibodies (preclinical collaboration)
Industry: Biotech

Drug pipeline

1 asset

tucatinib

Phase 2

Indications: HER2-positive metastatic breast cancer, HER2-positive metastatic colorectal cancer

Partnerships

Adimab – research collaboration for novel antibodies against immunotherapy targets[10]Sentinel Oncology – licensed preclinical Chk1 inhibitor[10]Pfizer – supported clinical trials involving tucatinib combinations[6]

Beyond the preview

Go deeper on Cascadian Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cascadian Therapeutics.

Explore the full profile